Eagle0 *There is no denying that the reported revenues are rising however fewer patient starts and steady patient discontinuations have in my view meant that patient recruitment has flatlined recently. *It must be remembered that none of these revenue numbers are audited and that there is some element of price increases included in revenue stats. *Q3 2024 revenue of US$91.2M was a 7.8% increase over Q2 2024 revenue. *My focus on unit sales is merely that this is a definitive number that can measured over a period of time to the exact day.In contrast the advice and timing of patient discontinuations is rubbery by its very nature *.Acadia earlier in the year downgraded its original 2024 revenue guidance from US$370M-US$420M to the current level of US$340M-$350M[say15%] which clearly indicated that a patient recruitment and retention problem had occurred. *In my view increasing net patient numbers is the only marker that matters -increased smallish revenue by itself is not what I hope to see . Kens
NEU Price at posting:
$13.12 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)